A QUALITY PRODUCT FROM TAJ PHARMACEUTICALS LIMITED NASAI Spray



Nasal Allergy Symptom **DU** NASAL ALLERGY SYMPTOMS INCLUDING CONGESTION, SNEEZING, ITCHY NOSE OR RUNNY NOSE.

USED JUST ONCE A DAY, EVERY DAY, AS DIRECTED BY YOUR DOCTOR, PRESCRIPTION NASORIL NASAL SPRAY IS CLINICALLY PROVEN TO TREAT INDOOR (OR "YEAR-ROUND") AND OUTDOOR (OR "SEASONAL") NASAL ALLERGY SYMPTOMS, EVERY MONTH YOU SUFFER.

NASORIL IS NON-HABIT-FORMING, SCENT-FREE AND ALCOHOL-FREE. IT IS NON-DROWSY AND WON'T KEEP YOU AWAKE. YOU CAN USE IT DAILY, ANY TIME OF THE YEAR YOU SUFFER, FOR AS LONG AS YOUR DOCTOR PRESCRIBES.

Nasoril Nasal Spray Mometasone Furoate Monohydrate

COMPOSITION

Each spray delivers: Mometasone Furoate Monohydrate USP 50 mcg Mometasone Furoate Monohydrate equivalent to: Mometasone Furoate USP...... 0.05% w/v Benzalkonium Chloride NF0.01% w/v (as preservative) Phenyl Ethyl Alcohol USP 0.25% v/v (as preservative)

INDICATIONS

NASORIL is indicated for the treatment of seasonal and perennial allergic rhinitis symptoms in adults and paediatric patients, 2 years of age and older. NASORIL is indicated for the prophylaxis of seasonal allergic rhinitis symptoms in adult and adolescent patients, 12 years and older. NASORIL is also indicated in the treatment of nasal polyps in those aged 18 and above.

DOSAGE AND ADMINISTRATION

Seasonal or Perennial Allergic Rhinitis

Adults and adolescents (12 years of age and older): The usual recommended dose is two sprays in each nostril once daily (total dose of 200 mcg). Once symptoms are controlled, dose reduction to one spray in each nostril (total dose of 100 mcg) may be effective for maintenance. If symptoms are inadequately controlled, the dose may be increased to a maximum dose of four sprays in each nostril once daily (total dose of 400 mcg). Dose reduction is recommended following control of symptoms.

NASORIL is indicated for the treatment

Children (between the ages of 6–11 years): The usual recommended dose is one spray in each nostril once daily (total dose of 100 mcg). NASORIL demonstrated a clinically significant onset of action within 12 hours after the first dose in some patients with seasonal allergic rhinitis; however, the full benefit of the treatment may not be achieved in the first 48 hours. Therefore, the patient should continue regular use to achieve full therapeutic benefit.







Nasal Polyposis

The usual recommended starting dose for polyposis is two sprays in each nostril once daily (total daily dose of 200 mcg). If after 5-6 weeks, symptoms are inadequately controlled, the dose may be increased to a dose of two sprays in each nostril twice daily (total daily dose of 400 mcg). The dose should be reduced following control of symptoms. If no improvement in symptoms is seen after 5-6 weeks of twice-daily administration, alternative therapies should be considered.

CONTRAINDICATIONS

Hypersensitivity to any of the ingredients of this preparation contraindicates its use.

PACKAGING INFORMATION

NASORIL NASAL SPRAY Sales pack contains 100 metered doses

Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited)

Updated on: July 2012 Source: Taj Pharmaceuticals Research and Development

ABOUT TAJ PHARMACEUTICALS GROUP

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufacturers pharmaceutical formulations and API for India and other countries of world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

MANUFACTURED IN INDIA BY:

Taj Pharmaceuticals Limited (INDIA)





Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is the later and a coefficient or provided provided provided and the later are set with a sub-field the later and access. subject to the terms and conditions as set out in our Privacy Policy and Terms of Use

© Copyright 2012 Taj Pharma Group (India),. All rights reserved.

Note:-We are committed to helping you find the right answers to your questions and concerns. However, this Report is not intended to give investment advice, promote the use of Taj Pharmaceuticals. Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider. Active Pharmaceutical Ingredients manufacture, exporter, drug ingredients, pharmaceuticals, India Additionally, contact information on this Report cannot be used to report adverse drug events. If you are a physician, please follow the procedures

required by your country's regulations. Please choose one of the given options to contact us and we will respond to